31 May 2022 in Frontiers in Surgery
Pulmonary arteriovenous fistula (PAVF) is a rare pulmonary vascular lesion, more than 80% of which is caused by congenital abnormal development of pulmonary capillaries. The incidence of PAVF ranges from 2/100,000 to 3/100,000, with no difference in the male and female ratio. Congenital PAVF is often associated with hereditary hemorrhagic telangiectasia (HHT). In this article, we report a patient with only congenital PAVF that was successfully treated by bilateral lung transplantation (BLT) with intraoperative venovenous extracorporeal membrane oxygenation (ECMO) support because both lungs have been affected by PAVF and secondary pulmonary hypertension. To the best of our knowledge, this is the first report of BLT for PAVF in China and the second report that explains the clinical course of a patient to receive BLT for congenital PAVF without HHT. Some investigators have proposed lung transplantation as a definitive treatment, but the results are controversial. On the basis of the current condition of this patient, we believe lung transplantation is a viable option for certain patients, but the long-term effect remains to be studied.
10 April 2024 in Research Square
To construct a practical prediction model for the risk of new-onset diabetes mellitus (DM) in patients with first-attack acute pancreatitis (AP) based on risk factors derived from demographic and clinical data. A total of 780 patients diagnosed with AP were retrospectively enrolled in the Second Affiliated Hospital of Nanchang University from June 2016 to June 2017. A series of exclusion criteria were applied and 396 patients were finally included. With a ratio of 2:1, patients were randomly divided into two groups named training (n = 264) and validation set (n = 132). Demographic and clinical data that may be risk factors of new-onset DM after first-attack AP were collected. Univariate and multivariate analyses were used to determine potential risk factors in the training set, and a predictive nomogram was constructed. Nomogram performance was determined in the training and validation sets concerning discrimination and calibration capabilities. Finally, clinical applicability of the nomogram was assessed in the validation set by decision curve analysis. The morbidity rate of new-onset DM after first-attack AP was 8.6% (34/396) in the included patient cohort. Hyperlipemia (OR = 6.87, 95%CI = 2.33 ~ 20.26, p = 0.000), GGT ≥ 40U/L (OR = 0.07, 95%CI = 0.03 ~ 0.27, p = 0.008), serum glucose ≥ 6.1mmol/L (OR = 7.73, 95%CI = 1.89 ~ 31.64, p = 0.004), CT grade ≥ 2 or 4 points (OR = 3.16 or 4.95, 95%CI = 1.05 ~ 9.45 or 1.12 ~ 21.89, p = 0.039 or 0.035) and APACHE II grade ≥ 8 points (OR = 3.82, 95%CI = 1.19 ~ 12.27, p = 0.024) were independent risk or protective factors and were assembled for nomogram construction. Internal and external validations showed good discrimination (Area under the receiver operating characteristic curve = 0.884 and 0.770) and calibration capabilities. The decision curve analysis showed good clinical applicability. We have developed a practical nomogram to predict the risk of new-onset DM after first-attack AP based on risk factors derived from demographic and clinical data, which would contribute to the identification and management of these high-risk patients.